Koppert, the world market leader in biological crop protection and Amoéba, an industrial greentech company, plan to introduce an innovative biofungicide to the market. 

Amoéba specializes in the development of natural microbiological solutions based on the patented use of amoeba. AXPERA is their innovative biological crop protection solution, an amoeba lysate-based biofungicide for combating fungal diseases. In the next coming weeks, Amoéba expects to receive the final assessment report on its active substance from the European Food Safety Environment (EFSA), which will pave the way for the use of its product AXPERA in Europe by the end of 2025. U.S. approval for the product AXPERA is expected mid of 2025 (approval for the active substance was granted in 2022).

Over the next five months, the two companies will cooperate in areas such as distribution, production, registration, financing and product (co-) development of AXPERA and new biocontrol products. Koppert and Amoéba will be working together to launch this innovative solution in the market.

About Amoéba 

Founded in 2010, Amoéba is a greentech company based in Chassieu (Lyon, France). Amoéba is currently the only company capable of exploiting the full potential of the Willaertia amoeba on an industrial scale and growing it in sufficient volumes to offer biological solutions that constitute a viable alternative to the chemical products widely used today.

Source: Koppert December 12, 2024 news release